中国新药杂志

作用于N-甲基-D-天门冬氨酸受体的抗抑郁药物的研究进展

PDF下载

宋文悦 , 高明奇 , 梁泽怀 , 秦瑜

中国新药杂志 | 综述 2021,30(15): 1396-1400

收起

中国新药杂志 |综述 2021 , 30 (15) : 1396 -1400

作用于N-甲基-D-天门冬氨酸受体的抗抑郁药物的研究进展

全屏

[Author(id=1322180337321492609, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=songwy1205@126.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322180337405378691, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, authorId=1322180337321492609, language=EN, stringName=Wen-yue SONG, firstName=Wen-yue, middleName=null, lastName=SONG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang 110000, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322180337506041988, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, authorId=1322180337321492609, language=CN, stringName=宋文悦, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医科大学药学院临床药理教研室，沈阳　110000, bio={"content":"

宋文悦，女，硕士研究生，主要从事抗抑郁症药物与抑郁症发病机制的研究。E-mail：songwy1205@126.com。

"}, bioImg=null, bioContent=

宋文悦，女，硕士研究生，主要从事抗抑郁症药物与抑郁症发病机制的研究。E-mail：songwy1205@126.com。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322180335622799485, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, xref=null, ext=[AuthorCompanyExt(id=1322180335631188094, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, companyId=1322180335622799485, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang 110000, China), AuthorCompanyExt(id=1322180335639576703, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, companyId=1322180335622799485, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医科大学药学院临床药理教研室，沈阳　110000)])]), Author(id=1322180337594122374, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=mqgao26@cmu.edu.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322180337682202760, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, authorId=1322180337594122374, language=EN, stringName=Ming-qi GAO, firstName=Ming-qi, middleName=null, lastName=GAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang 110000, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322180337761894537, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, authorId=1322180337594122374, language=CN, stringName=高明奇, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医科大学药学院临床药理教研室，沈阳　110000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322180335622799485, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, xref=null, ext=[AuthorCompanyExt(id=1322180335631188094, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, companyId=1322180335622799485, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang 110000, China), AuthorCompanyExt(id=1322180335639576703, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, companyId=1322180335622799485, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医科大学药学院临床药理教研室，沈阳　110000)])]), Author(id=1322180337883529355, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322180337988386957, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, authorId=1322180337883529355, language=EN, stringName=Ze-huai LIANG, firstName=Ze-huai, middleName=null, lastName=LIANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang 110000, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322180338076467342, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, authorId=1322180337883529355, language=CN, stringName=梁泽怀, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医科大学药学院临床药理教研室，沈阳　110000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322180335622799485, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, xref=null, ext=[AuthorCompanyExt(id=1322180335631188094, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, companyId=1322180335622799485, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang 110000, China), AuthorCompanyExt(id=1322180335639576703, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, companyId=1322180335622799485, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医科大学药学院临床药理教研室，沈阳　110000)])]), Author(id=1322180338147770512, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322180338240045202, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, authorId=1322180338147770512, language=EN, stringName=Yu QIN, firstName=Yu, middleName=null, lastName=QIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang 110000, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322180338319736979, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, authorId=1322180338147770512, language=CN, stringName=秦瑜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医科大学药学院临床药理教研室，沈阳　110000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322180335622799485, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, xref=null, ext=[AuthorCompanyExt(id=1322180335631188094, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, companyId=1322180335622799485, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang 110000, China), AuthorCompanyExt(id=1322180335639576703, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180334926545018, companyId=1322180335622799485, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医科大学药学院临床药理教研室，沈阳　110000)])])]

宋文悦, 高明奇, 梁泽怀, 秦瑜

作者信息

中国医科大学药学院临床药理教研室，沈阳　110000

通讯作者:

高明奇，男，教授，主要从事抗抑郁症药物与抑郁症发病机制的研究。E-mail：mqgao26@cmu.edu.cn。

作者简介:

宋文悦，女，硕士研究生，主要从事抗抑郁症药物与抑郁症发病机制的研究。E-mail：songwy1205@126.com。

Research advances of NMDA receptor antagonists for the treatment of antidepressant

Wen-yue SONG, Ming-qi GAO, Ze-huai LIANG, Yu QIN

Affiliations

Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang 110000, China

出版时间: 2021-08-15

文章导航

摘要

收起

抑郁症是一种常见的神经系统障碍疾病，目前其发病机制尚不明确。谷氨酸是中枢神经系统中主要的兴奋性神经递质，越来越多的证据表明谷氨酸能系统在抑郁症的发生发展中起关键作用。作用于N-甲基-D-天门冬氨酸（NMDA）受体（NMDAR）的抗抑郁药能产生快速持久强效的抗抑郁作用，是开发新型抗抑郁药的重要靶点之一。本文将围绕NMDAR系统，对不同的NMDAR的非选择性抑制剂和选择性抑制剂（选择性NR2B受体抑制剂）的抗抑郁作用及其研究现状进行综述，以期为新型抗抑郁药的开发和抑郁症的治疗提供新的依据。

关键词

抗抑郁药 / N-甲基-D-天门冬氨酸受体 / N-甲基-D-天门冬氨酸受体抑制剂 / 氯胺酮 / 选择性NR2B受体抑制剂

Abstract

收起

Depression is a common neurological disorder, the pathogenesis of which is still unclear. Glu-tamate is one of the major excitatory neurotransmitters in the central nervous system. Increasing evidences show that glutamatergic system plays a key role in the occurrence and development of depression. In antidepressant therapy, NMDA receptor antagonists can produce rapid and lasting antidepressant effects, which is one of the important targets for the development of new anti-depressants. This article will focus on the glutamatergic system, and summarize the effects of antidepressant and research status of different non-selective NMDA receptor antagonists and selective NMDA receptor antagonists [subunit (NR2B)-specific NMDA receptor antagonists], providing new basis for the development of novel antidepressants and the treatment of depression.

Key words

antidepressant / NMDA receptor / NMDA receptor antagonists / ketamine / subunit (NR2B)-specific NMDA receptor antagonists

引用本文

宋文悦, 高明奇, 梁泽怀, 秦瑜. 作用于N-甲基-D-天门冬氨酸受体的抗抑郁药物的研究进展. 中国新药杂志, 2021 , 30 (15) : 1396 -1400 .

Wen-yue SONG, Ming-qi GAO, Ze-huai LIANG, Yu QIN. Research advances of NMDA receptor antagonists for the treatment of antidepressant[J]. Chinese Journal of New Drugs, 2021 , 30 (15) : 1396 -1400 .

基金

收起

辽宁省自然科学基金资助项目(LFWK201723)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

王宇红, 张尚霞, 马明玥, 等. 复方柴金解郁片对慢性应激抑郁大鼠HPA轴及炎症因子的影响[J]. 中国新药杂志, 2020, 29(5): 514-519.

[2]

SMITH K. Mental health: a world of depression[J]. Nature, 2014, 515(7526): 181.

[3]

HUANG Y, WANG Y, WANG H, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study[J]. Lancet Psychiatry, 2019, 6(3): 211-224.

[4]

黄吉生, 杜金平, 徐砚通. 快速起效抗抑郁药物研究进展[J]. 中国新药杂志, 2015, 24(23), 24: 2669-2676.

[5]

邓朔, 张鸿燕. 抑郁症发病机制的神经免疫相关靶点研究现状[J]. 中国临床药理学杂志, 2017, 33(3): 280-283.

[6]

LENER MS, KADRIU B, ZARATE CA Jr. Ketamine and beyond: investigations into the potential of glutamatergic agents to treat depression[J]. Drugs, 2017, 77(4): 381-401.

[7]

O'BRIEN DE, CONN PJ. Neurobiological insights from mGlu receptor allosteric modula-tion[J]. Int J Neuropsychopharmacol, 2016, 19(5): 133.

[8]

SERTER KOCOGLU S, GOK YURTSEVEN D, CAKIR C, et al. Glutamatergic activation of neuronostatin neurons in the periventricular nucleus of the hypothalamus[J]. Brain Sci, 2020, 10(4): e217.

[9]

BLIZNYUK A, HOLLMANN M, GROSSMAN Y. High pressure stress response: in-volvement of NMDA receptor subtypes and molecular markers[J]. Front Physiol, 2019, 10: 1234.

[10]

刘学文, 胥向红, 杨锐, 等. W-7对NMDA诱导的体外培养神经元凋亡的保护作用及机制[J]. 中国新药杂志, 2011, 20(14): 1330-1333.

[11]

IYASWAMY A, KAMMELLA AK, THAVASIMUTHU C, et al. Oxidative stress evoked damages leading to attenuated memory and inhibition of NMDAR-CaMKII-ERK/CREB signalling on consumption of aspartame in rat model[J]. J Food Drug Anal, 2018, 26(2): 903-916.

[12]

MONTES DE OCA BALDERAS P. Flux-independent NMDAR signaling: molecular me-diators, cellular functions, and complexities[J]. Int J Mol Sci, 2018, 19(12): E3800.

[13]

LIU YM, ZHAO N, LI CC, et al. Longistyline C Acts antidepressant in vivo and neuro-protection in vitro against glutamate-induced cytotoxicity by regulating NMDAR/NR2B-ERK pathway in PC12 cells[J]. PLoS One, 2017, 12(9): e0183702.

[14]

SRIVASTAVA P, DHURIYA YK, KUMAR V, et al. PI3K/Akt/GSK3β induced CREB ac-tivation ameliorates arsenic mediated alterations in NMDA receptors and associated sig-naling in rat hippocampus: Neuroprotective role of curcumin[J]. Neurotoxicology, 2018, 67: 190-205.

[15]

SANACORA G, ZARATE CA, KRYSTAL JH, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders[J]. Nat Rev Drug Discov, 2008, 7(5): 426-437.

[16]

BERMAN RM, CAPPIELLO A, ANAND A, et al. Antidepressant effects of ketamine in depressed patients[J]. Biol Psychiatry, 2000, 47(4): 351-354.

[17]

MURROUGH JW, IOSIFESCU DV, CHANG LC, et al. Antidepressant efficacy of keta-mine in treatment-resistant major depression: a two-site randomized controlled trial[J]. Am J Psychiatry, 2013, 170(10): 1134-1142.

[18]

WILKINSON ST, BALLARD ED, BLOCH MH, et al. The effect of a single dose of in-travenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis[J]. Am J Psychiatry, 2018, 175(2): 150-158.

[19]

CHILUKURI H, REDDY NP, PATHAPATI RM, et al. Acute antidepressant effects of intramuscular versus intravenous ketamine[J]. Indian J Psychol Med, 2014, 36(1): 71-76.

[20]

DE GIOANNIS A, DE LEO D. Oral ketamine augmentation for chronic suicidality in treatment-resistant depression[J]. Aust N Z J Psychiatry, 2014, 48(7): 686.

[21]

ANDRADE C. Oral ketamine for depression, 1: pharmacologic considerations and clinical evidence[J]. J Clin Psychiatry, 2019, 80(2): 19f12820.

[22]

RÉUS GZ, STRINGARI RB, RIBEIRO KF, et al. Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain[J]. Behav Brain Res, 2011, 221(1): 166-171.

[23]

LEPACK AE, FUCHIKAMI M, DWYER JM, et al. BDNF release is required for the behavioral actions of ketamine[J]. Int J Neuropsychopharmacol, 2014, 18(1): 1-6.

[24]

TORNESE P, SALA N, BONINI D, et al. Chronic mild stress induces anhedonic behavior and changes in glutamate release, BDNF trafficking and dendrite morphology only in stress vulnerable rats. The rapid restorative action of ketamine[J]. Neurobiol Stress, 2019, 10: 100160.

[25]

YANG C, REN Q, QU YG, et al. Mechanistic target of rapamycin-independent antide-pressant effects of (R)-ketamine in a social defeat stress model[J]. Biol Psychiatry, 2018, 83(1): 18-28.

[26]

NOWAK W, GRENDAS LN, SANMARCO LM, et al. Pro-inflammatory monocyte profile in patients with major depressive disorder and suicide behaviour and how ketamine induces anti-inflammatory M2 macrophages by NMDAR and mTOR[J]. E Bio Medicine, 2019, 50: 290-305.

[27]

AUTRY AE, ADACHI M, NOSYREVA E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses[J]. Nature, 2011, 475(7354): 91-95.

[28]

YANG BK, REN Q, MA M, et al. Antidepressant effects of (+)-MK-801 and (-)-MK-801 in the social defeat stress model[J]. Int J Neuropsychopharmacol, 2016, 19(12): pyw080.

[29]

YANG BK, QIN J, NIE Y, et al. Sustained antidepressant action of the N-methyl-D-aspartate receptor antagonist MK-801 in a chronic unpredictable mild stress model[J]. Exp Ther Med, 2018, 16(6): 5376-5383.

[30]

POCHWAT B, RAFAŁO-ULIŃSKA A, DOMIN H, et al. Involvement of extracellular signal-regulated kinase (ERK) in the short and long-lasting antidepressant-like activity of NMDA receptor antagonists (zinc and Ro 25-6981) in the forced swim test in rats[J]. Neuropharmacology, 2017, 125: 333-342.

[31]

LI NX, LIU RJ, DWYER JM, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure[J]. Biol Psychiatry, 2011, 69(8): 754-761.

[32]

LIMA-OJEDA JM, VOGT MA, PFEIFFER N, et al. Pharmacological blockade of GluN2B-containing NMDA receptors induces antidepressant-like effects lacking psy-chotomimetic action and neurotoxicity in the perinatal and adult rodent brain[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2013, 45: 28-33.

[33]

TALBOT JN, GEFFERT LM, JORVIG JE, et al. Rapid and sustained antidepressant properties of an NMDA antagonist/monoamine reuptake inhibitor identified via trans-porter-based virtual screening[J]. Pharmacol Biochem Behav, 2016, 150-151: 22-30.

[34]

YELLEPEDDI VK, ZHUDEVA MY, MOVAHEDI F, et al. Biopharmaceutical character-ization and oral efficacy of a new rapid acting antidepressant ro 25-6981[J]. J Pharm Sci, 2018, 107(9): 2472-2478.

[35]

PRESKORN SH, BAKER B, KOLLURI S, et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101, 606, in patients with treatment-refractory major depressive disorder[J]. J Clin Psychopharmacol, 2008, 28(6): 631-637.

[36]

STASIUK W, SEREFKO A, SZOPA A, et al. Traxoprodil augments the antidepressant-like activity of agomelatine but not of mianserin or tianeptine in the forced swim test in mice[J]. Pharmacol Rep, 2016, 68(5): 960-963.

[37]

STASIUK W, SZOPA A, SEREFKO A, et al. Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice[J]. J Neural Transm (Vienna), 2017, 124(3): 387-396.

[38]

TANG HY, KUKRAL D, LI YW, et al. Mapping the central effects of (±)-ketamine and traxoprodil using pharmacological magnetic resonance imaging in awake rats[J]. J Psychopharmacol, 2018, 32(2): 146-155.

[39]

BECKER R, GASS N, KUßMAUL L, et al. NMDA receptor antagonists traxoprodil and lanicemine improve hippocampal-prefrontal coupling and reward-related networks in rats[J]. Psychopharmacology (Berl), 2019, 236(12): 3451-3463.

[40]

IBRAHIM L, DIAZ GRANADOS N, JOLKOVSKY L, et al. A Randomized, place-bo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in pa-tients with treatment-resistant major depressive disorder[J]. J Clin Psychopharmacol, 2012, 32(4): 551-557.

[41]

GARNER R, GOPALAKRISHNAN S, MCCAULEY JA, et al. Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist[J]. Pharmacol Res Perspect, 2015, 3(6): e00198.

[42]

ZHOU W, WANG N, YANG C, et al. Ketamine-induced antidepressant effects are associ-ated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat Hippocampus and prefrontal cortex[J]. Eur Psychiatry, 2014, 29(7): 419-423.

[43]

FARLEY S, APAZOGLOU K, WITKIN JM, et al. Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm[J]. Int J Neuropsychopharmacol, 2010, 13(9): 1207-1218.

[44]

ANDREASEN JT, FITZPATRICK CM, LARSEN M, et al. Differential role of AMPA receptors in mouse tests of antidepressant and anxiolytic action[J]. Brain Res, 2015, 1601: 117-126.

[45]

NATIONS KR, DOGTEROM P, BURSI R, et al. Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial[J]. J Psychopharmacol, 2012, 26(12): 1525-1539.

[46]

PALUCHA A, BRANSKI P, SZEWCZYK B, et al. Potential anti-addictive effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist[J]. Eur Neuropsychopharmacol, 2002, 12: 390.

[47]

BELOZERTSEVA IV, KOS T, POPIK P, et al. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests[J]. Eur Neuropsychopharmacol, 2007, 17(3): 172-179.

[48]

LINDEMANN L, PORTER RH, SCHARF SH, et al. Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression[J]. J Pharmacol Exp Ther, 2015, 353(1): 213-233.

[49]

DONG C, ZHANG JC, YAO W, et al. Rapid and sustained antidepressant action of the mGlu2/3 receptor antagonist MGS0039 in the social defeat stress model: comparison with ketamine[J]. Int J Neuropsychopharmacol, 2017, 20(3): 228-236.

[50]

苑杰, 姜伟时, 刘颖, 等. 抗抑郁药的药效学性别异质性研究进展[J]. 中国现代应用药学, 2019, 36(11): 1443-1447.

[51]

PODKOWA K, POCHWAT B, BRAŃSKI P, et al. Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats[J]. Psychopharmacology (Berl), 2016, 233(15-16): 2901-2914.

2021年第30卷第15期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-28
出版时间：2021-08-15

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2020-11-29

基金

辽宁省自然科学基金资助项目(LFWK201723)

作者信息

中国医科大学药学院临床药理教研室，沈阳　110000

通讯作者:

高明奇，男，教授，主要从事抗抑郁症药物与抑郁症发病机制的研究。E-mail：mqgao26@cmu.edu.cn。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322180334926545018

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT